{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["97(7)"],"submitter":["Gozzetti A"],"pubmed_abstract":["Monoclonal gammopathy of renal significance (MGRS) is a recognized clinical entity. Literature regarding treatment and its outcomes in MGRS is sparse due to the rarity and misdiagnosis of MGRS. We retrospectively analyzed 280 adults with an MGRS diagnosis from 2003 to 2020 across 19 clinical centers from 12 countries. All cases required renal biopsy for the pathological diagnosis of MGRS. Amyloidosis-related to MGRS (MGRS-A) was present in 180 patients; nonamyloidosis MGRS (MGRS-NA), including a broad spectrum of renal pathologies, was diagnosed in 100 patients. The median overall survival in the studied cohort was 121.0 months (95% CI: 105.0-121.0). Patients with MGRS-A had a shorter overall survival than patients with MGRS-NA (HR = 0.41, 95%CI: 0.25-0.69; p = 0.0007). Both hematologic an"],"journal":["American journal of hematology"],"pagination":["877-884"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9324084"],"repository":["biostudies-literature"],"pubmed_title":["Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors."],"pmcid":["PMC9324084"],"pubmed_authors":["Zamagni E","Waszczuk-Gajda A","Mateos MV","Cavo M","Gozzetti A","Vesole DH","Crusoe E","Chhabra S","Davila J","Usnarska-Zubkiewicz L","Guarnieri A","Coriu D","Fullgraf H","Schutz N","Rassner M","Bhasin-Chhabra B","Pika T","Avivi I","Gentile M","Charlinski G","Jurczyszyn A","Einsele H","Bittrich M","Bocchia M","Zakharova E","Pena C","Thapa B","Gonzalez-Calle V","Rocchi S","Bigi F","Legiec W","Tovar N","Ciofini S"],"additional_accession":[]},"is_claimable":false,"name":"Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors.","description":"Monoclonal gammopathy of renal significance (MGRS) is a recognized clinical entity. Literature regarding treatment and its outcomes in MGRS is sparse due to the rarity and misdiagnosis of MGRS. We retrospectively analyzed 280 adults with an MGRS diagnosis from 2003 to 2020 across 19 clinical centers from 12 countries. All cases required renal biopsy for the pathological diagnosis of MGRS. Amyloidosis-related to MGRS (MGRS-A) was present in 180 patients; nonamyloidosis MGRS (MGRS-NA), including a broad spectrum of renal pathologies, was diagnosed in 100 patients. The median overall survival in the studied cohort was 121.0 months (95% CI: 105.0-121.0). Patients with MGRS-A had a shorter overall survival than patients with MGRS-NA (HR = 0.41, 95%CI: 0.25-0.69; p = 0.0007). Both hematologic an","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-26T16:20:21.056Z","creation":"2025-04-06T15:09:01.371Z"},"accession":"S-EPMC9324084","cross_references":{"pubmed":["35389534"],"doi":["10.1002/ajh.26566"]}}